Beauty Health (NASDAQ:SKIN) Announces Earnings Results, Beats Estimates By $0.01 EPS

Beauty Health (NASDAQ:SKIN) released its quarterly earnings results on Thursday. The company reported ($0.06) earnings per share for the quarter, beating the consensus estimate of ($0.07) by $0.01, FiscalAI reports. Beauty Health had a negative net margin of 3.87% and a negative return on equity of 19.70%. The firm had revenue of $82.40 million for the quarter, compared to analysts’ expectations of $78.07 million.

Beauty Health Price Performance

Beauty Health stock traded down $0.07 during mid-day trading on Thursday, reaching $1.06. 912,624 shares of the company were exchanged, compared to its average volume of 613,356. The firm has a market cap of $135.15 million, a PE ratio of -4.82 and a beta of 1.20. The company has a debt-to-equity ratio of 5.53, a current ratio of 4.98 and a quick ratio of 4.07. The company has a fifty day simple moving average of $1.28 and a 200-day simple moving average of $1.53. Beauty Health has a 12 month low of $0.78 and a 12 month high of $2.69.

Institutional Investors Weigh In On Beauty Health

Several institutional investors and hedge funds have recently bought and sold shares of the company. Woodline Partners LP increased its holdings in shares of Beauty Health by 255.9% during the third quarter. Woodline Partners LP now owns 5,930,027 shares of the company’s stock worth $11,801,000 after buying an additional 4,263,997 shares in the last quarter. Millennium Management LLC boosted its holdings in shares of Beauty Health by 127.0% during the 4th quarter. Millennium Management LLC now owns 5,764,802 shares of the company’s stock valued at $8,013,000 after acquiring an additional 3,225,668 shares in the last quarter. Soleus Capital Management L.P. bought a new stake in Beauty Health during the 2nd quarter worth $1,910,000. Geode Capital Management LLC increased its holdings in Beauty Health by 27.5% in the 2nd quarter. Geode Capital Management LLC now owns 2,302,784 shares of the company’s stock worth $4,399,000 after purchasing an additional 496,963 shares in the last quarter. Finally, Bank of America Corp DE raised its position in Beauty Health by 482.3% in the third quarter. Bank of America Corp DE now owns 336,382 shares of the company’s stock valued at $669,000 after purchasing an additional 278,616 shares during the last quarter. Institutional investors own 93.26% of the company’s stock.

Key Stories Impacting Beauty Health

Here are the key news stories impacting Beauty Health this week:

• Positive Sentiment: Q4 results: SKIN reported GAAP EPS of ($0.06), beating consensus by $0.01, and revenue of $82.4M vs. $78.1M expected — a clear top-line and EPS beat that validates recent demand for Hydrafacial and related products. View Press Release
• Neutral Sentiment: Company press release: Full-year and Q4 2025 financial results posted to GlobeNewswire providing detailed metrics and commentary on performance. Useful for modelers but largely reiterates the beats above. BeautyHealth Reports Full Year and Fourth Quarter 2025 Financial Results
• Neutral Sentiment: Industry/market coverage: Several consumer and skincare articles were published (India skincare shift, consumer features) that are background-positive for the category but do not directly affect SKIN’s near-term guidance or financials. From Beauty to Healthy Skin: How Glowderma Is Leading India’s Science-Backed (Dermatology-Led) Skincare Shift
• Negative Sentiment: Q1 2026 guidance: Revenue guidance lowered to $63.0M–$68.0M vs. the Street estimate of ~$68.6M — the midpoint and upper end sit below consensus, signaling a softer start to 2026 and prompting near-term downside pressure.
• Negative Sentiment: FY 2026 guidance: Full-year revenue range set at $285.0M–$305.0M vs. consensus ~$304.6M — the top end is essentially flat-to-slightly below Street expectations, leaving limited upside and raising questions about margin recovery and growth pacing.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on SKIN shares. Zacks Research cut Beauty Health from a “hold” rating to a “strong sell” rating in a report on Wednesday, January 21st. TD Cowen increased their price objective on Beauty Health from $1.50 to $1.65 and gave the stock a “hold” rating in a research report on Wednesday, January 21st. Finally, Jefferies Financial Group reissued a “hold” rating and issued a $1.60 target price on shares of Beauty Health in a research report on Wednesday, January 14th. One equities research analyst has rated the stock with a Buy rating, four have given a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Reduce” and an average target price of $2.40.

About Beauty Health

Beauty Health Company (NASDAQ: SKIN) is a U.S.-based consumer wellness and beauty enterprise that integrates device-based and product-based offerings across skin, body and hair wellness categories. The company operates a portfolio of established brands that blend professional and at-home solutions, focusing on innovative formulations and technologies to address a range of beauty and self-care needs. Through its proprietary e-commerce platforms and strategic retail partnerships, Beauty Health seeks to deliver premium experiences and tangible results to a global customer base.

Beauty Health’s brand portfolio includes Sol de Janeiro, known for its award-winning Brazilian Bum Bum Cream body care collection; Elemis, a U.K.-originated professional skin care line distributed in spas and skincare clinics; NuFACE and Dermaflash, two at-home beauty device brands specializing in microcurrent facial toning and gentle exfoliation respectively; and Nutrafol, a legal-strength hair wellness supplement clinically designed to support hair growth.